Stock Track | Moderna Soars 5.06% Intraday on AI-Powered Personalized Vaccine Story Highlighting mRNA Potential

Stock Track03-17 23:16

Moderna, Inc. (MRNA) saw its stock price soar 5.06% during intraday trading on Tuesday, marking a significant upward movement for the mRNA vaccine maker.

The surge appears linked to investor optimism following a widely reported story about a tech executive who used AI tools like ChatGPT and Google's DeepFold to design a personalized cancer vaccine for his dog. Investment commentators highlighted that this real-world example showcases the emerging potential of "programmable medicine," a field where Moderna's mRNA technology is seen as a key enabler.

Further bolstering sentiment, recent regulatory developments were noted, including draft guidance from the U.S. Food and Drug Administration for targeted individualized therapies, which specifically referenced RNA-based treatments. This combination of a tangible AI-medicine breakthrough and a supportive regulatory environment for personalized therapies is driving positive reassessment of Moderna's long-term prospects in the evolving biotech landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116408917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116408917","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.06% Intraday on AI-Powered Personalized Vaccine Story Highlighting mRNA Potential","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) saw its stock price soar 5.06% during intraday trading on Tuesday, marking a significant upward movement for the mRNA vaccine maker.</p><p>The surge appears linked to investor optimism following a widely reported story about a tech executive who used AI tools like ChatGPT and Google's DeepFold to design a personalized cancer vaccine for his dog. Investment commentators highlighted that this real-world example showcases the emerging potential of \"programmable medicine,\" a field where Moderna's mRNA technology is seen as a key enabler.</p><p>Further bolstering sentiment, recent regulatory developments were noted, including draft guidance from the U.S. Food and Drug Administration for targeted individualized therapies, which specifically referenced RNA-based treatments. This combination of a tangible AI-medicine breakthrough and a supportive regulatory environment for personalized therapies is driving positive reassessment of Moderna's long-term prospects in the evolving biotech landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.06% Intraday on AI-Powered Personalized Vaccine Story Highlighting mRNA Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.06% Intraday on AI-Powered Personalized Vaccine Story Highlighting mRNA Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-17 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) saw its stock price soar 5.06% during intraday trading on Tuesday, marking a significant upward movement for the mRNA vaccine maker.</p><p>The surge appears linked to investor optimism following a widely reported story about a tech executive who used AI tools like ChatGPT and Google's DeepFold to design a personalized cancer vaccine for his dog. Investment commentators highlighted that this real-world example showcases the emerging potential of \"programmable medicine,\" a field where Moderna's mRNA technology is seen as a key enabler.</p><p>Further bolstering sentiment, recent regulatory developments were noted, including draft guidance from the U.S. Food and Drug Administration for targeted individualized therapies, which specifically referenced RNA-based treatments. This combination of a tangible AI-medicine breakthrough and a supportive regulatory environment for personalized therapies is driving positive reassessment of Moderna's long-term prospects in the evolving biotech landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1116408917","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116408917","pubTimestamp":1773760602,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) saw its stock price soar 5.06% during intraday trading on Tuesday, marking a significant upward movement for the mRNA vaccine maker.The surge appears linked to investor optimism...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna盘中大涨5.06%AI驱动的个性化疫苗故事凸显mRNA潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) saw its stock price soar 5.06% during intraday trading on Tuesday, marking a significant upward movement for the mRNA vaccine maker.The surge appears linked to investor optimism following a widely reported story about a tech executive who used AI tools like ChatGPT and Google's DeepFold to design a personalized cancer vaccine for his dog. Investment commentators highlighted that this real-world example showcases the emerging potential of \"programmable medicine,\" a field where Moderna's mRNA technology is seen as a key enabler.Further bolstering sentiment, recent regulatory developments were noted, including draft guidance from the U.S. Food and Drug Administration for targeted individualized therapies, which specifically referenced RNA-based treatments. This combination of a tangible AI-medicine breakthrough and a supportive regulatory environment for personalized therapies is driving positive reassessment of Moderna's long-term prospects in the evolving biotech landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116408917","isCrawlerRequest":true}